Abstract Body

Background

Bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) is an efficacious and preferable regimen in many contexts, but experience of its use in people with pre-existing HIV-1 nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) beyond M184V remains limited. TAF is thought to exert higher activity against virus with tenofovir mutations owing to high intracellular concentration, suggesting potential utility in this cohort.

Methods

Single-centre retrospective analysis of people with pre-existing NRTI RAMs, no integrase strand transfer inhibitor (INSTI) RAMS, who were prescribed BFTAF between 22/Nov/2019 and 27/Jun/2025. Data collected during routine clinical care included demographic data, ART prescription, HIV-1 viral loads, genotypic resistance testing, and clinical outcomes. Results presented as absolute numbers (%) or medians (interquartile range, IQR).

Results

Data from 238 eligible people were analysed. Median age of participants was 59y (54-63); 77.3% male; 55.9% white. Median number of NRTI RAMs was 2 (IQR 1-3.76, range 1-10). 165 (69.3%) participants had M184V; the sole mutation for 80/238 (33.6%) (48.5% of those with M184V). 98 (41.2%) participants had 1 or more thymidine analogue mutations (TAM), and 12 (5.1%) had K65R/N. Median exposure to BFTAF was 829 days (394-1163), 203 (85.2%) continued BFTAF at the end of the period. 174 (73.1%) had undetectable HIV-1 RNA (<40 copies/mL) throughout BFTAF therapy. 

Eight (3.4%) of participants had confirmed virological failure (VF), with the majority of viraemias being attributable to being detectable at time of switch to BFTAF (n=17), non-adherence to ART (n=24), or isolated viral blips (n=14). None of the 12 participants with K65R/N developed VF, and 5 also had M184V. Four (4.1%) participants with TAMs developed VF; 3/4 had ≥3 TAMs; 2/3 had low level viraemia (LLV) only. A mixed pattern of Type 1 and Type 2 TAMs was seen. Four episodes of persistent LLV occurred in participants with only M184V (n=2) or accessory TAMs (n=2) only and were felt to be attributable to adherence issues. No participants with VF developed significant INSTI RAMs.

Conclusions

Our data provides further evidence that B/F/TAF is a safe and effective regimen for use in people with pre-existing NRTI resistance including M184V, K65R/N and TAMs, with very few patients developing VF. VF predominantly appeared to be driven by non-adherence irrespective of NRTI resistance.